

The Executive Office of Health & Human Services



Pharmacy and Therapeutics Committee Meeting Minutes

Tuesday, June 7th, 2022

8:00 AM

Gainwell Technologies

Location: OHHS Virks Building, 3 West Rd, Cranston, RI

P & T Members Present: Todd Brothers, PharmD
Nickolai Morin, PharmD
Bill Quirk, RPh
Matt Salisbury, MD
Rick Wagner, MD

Absent: Greg Allen, MD
Tracey Tavieria, PharmD

Others Present: Ann Bennett, MHA (Gainwell Technologies)
Jerry Fingerut, MD, Medical Director, (EOHHS)
Karen Mariano, RPh (Gainwell Technologies)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:05 am. Co-Chairman Todd Brothers called the meeting to order and asked for introductions the committee and those supporting the meeting. The April 12th, 2022 meeting minutes were reviewed and by vote were accepted as presented.

Public testimony included the following speakers and topics.

Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

P & T Speakers	Affiliation	Topic
Amy Tomasella	Otsuka	Rexulti
Timothy Birner	Alkermes	Lybalvi
Steven Burch	Sunovion	Latuda
Jane Gao	Novartis	Cosentyx
Kristin Kollecass	Sanofi	Dupixent
Alain Nguyen	Gilead	Hepatitis C
Catherine Pian	Intracellular Therapies	Caplyta
Matthew Stryker	Amgen	Tezpire
Aaron Walter	Pfizer	Cibinqo
Alvin Ono	Leo Pharma	Adbry
Melissa Porricelli	NovoNordisk	Wegovy

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

Therapeutic Categories				Vote: Yes	Vote: No	Abstain	Motion
Anti-infectives	Antibiotics	GI	Comments: Expanded indications Solosec, product discontinued brand Flagyl. Updated guidelines.	5	0	0	Passes
		Vaginal	USPTF statement on screening for chlamydia and gonorrhea. Recommendation to non-prefer vandazole.	5	0	0	Passes
	Antifungals	Oral	New product Brexafemme. Expanded indications for Noxafil. Recommend prefer Noxafil.	5	0	0	Passes
	Antivirals	HSV	Recommendation to non-prefer famciclovir.	5	0	0	Passes
		Influenza	Labeling update Xofluza. No changes recommended.	5	0	0	Passes
	Cephalosporins & Related Antibiotics		No changes recommended.	5	0	0	Passes
	Fluoroquinolones		No changes recommended.	5	0	0	Passes
	Hepatitis C Agents		Expanded indications Epclusa and Mavyret to 3 yoa. Zepatier expanded indication to 12 yoa. Question: what is being seen across the country? Several different models. Each State looks at budget, prevalence, infection rates. RI has initiative to eradicate hepatitis C with RIHAC. No changes recommended.	4	0	1	Passes
	HIV Agents		All oral products are preferred. Question: have other states restricted this category? Yes. Some states are managing by brand vs. generic. Another approach is to look at single tablet regimens and compliance to regimens. DUR to look at what tis most efficacious long term. Some state removing drugs are no longer consistent with guidelines. No changes recommended.	5	0	0	Passes
CNS Agents	Macrolides-Ketolides	Oral	No changes recommended.	5	0	0	Passes
	Tetracycline		No changes recommended.	5	0	0	Passes
	Antipsychotics		REMS update Adasuve. Currently the product is not federally rebatable and therefore not on the PDL. Recommendations in the category: prefer Invega Hafyera; Non-prefer paliperidone and the authorized generic.	5	0	0	Passes
Dermatological	Acne Agents		New product Twyneo (combination). New generics in the category. Compliance is low in the class related to wrap. Recommendations: add Cleocin T lotion, Differin Gel pump, Epiduo Forte Gel pump and Retin-A gel.	5	0	0	Passes
	Antibiotics	Topical	No changes recommended.	5	0	0	Passes
	Antifungals	Topical	No changes recommended.	5	0	0	Passes
	Antipsoriatics	Topical	No changes to PDL. Commentary: are states beginning to step through the guidelines ? Yes.	5	0	0	Passes
	Antiviral Agents	Topical	Recommendations: non-prefer Zovirax cream and prefer Acyclovir ointment.	5	0	0	Passes

Continued categories for therapeutic class reviews.

Therapeutic Categories				Vote: Yes	Vote: No	Abstain	Motion
Immunologic	Immunomodulators	Atopic Dermatitis	New product information: Opzelura, Adbry. Expanded indications: Dupixent. ICER report new guidance comparing the clinical effectiveness and value of therapies for atopic dermatitis. Low compliance; low utilization. Preferred agent Elidel and Eucrisa. Comments: Given that most people in MCO is this whole use of biologics looked at across going from FFS and MCO, discontinuation problem. Consider a single structure across FFS and MCOs. Recommend non-prefer Protopic.	5	0	0	Passes
	Immunomodulators	Topical, Summary	No changes recommended.	5	0	0	Passes
	Rosacea Agents	Topical	No changes recommended.	5	0	0	Passes
	Steroids		Recommendations as follows: Low, no change; moderate, no change; high, recommend addition of betamet diprop/prop gly cream; very high, non-prefer clobetasol prop gel.	5	0	0	Passes
	Cytokine & CAM Agents		New product Cibirgo. Updated information Cosentyx, Olumiant, Orcencia, Rinvoq, Skyrizi, Xeljanz/XR and Actemra IV formulation. Boxed warning updates on Xeljanz/XR, Olumiant and Rinvoq. No changes recommended.	5	0	0	Passes
	Methotrexate Agents		No changes recommended. Question: where does chloroquine or hydroxychloroquine fit in? Follow up.	5	0	0	Passes
	Anti-allergens	Oral	No changes recommended.	5	0	0	Passes
	Antibiotics	Inhaled	No changes recommended.	5	0	0	Passes
	Antihistamines	Minimally Sedating	No changes recommended.	5	0	0	Passes
	Bronchodilators	Beta Agonists	New generics in the category. Recommend adding Proventil HFA.	5	0	0	Passes
	COPD Agents		No changes recommended. Comments: Consider updated guidelines for future recommendations. Should this class be split in the future between asthma and COPD. Difficult to assess compliance going forward.	5	0	0	Passes
	Epinephrine	Self-Injected	No changes to PDL. Compliance is low. Supply issues improving. Recommend adding EpiPen and EpiPen JR to the PDL.	5	0	0	Passes
	Glucocorticoids	Inhaled	Updated information ArmonAir Digihaler. New Generic for Symbicort. No changes recommended. Commentary: Does it makes sense to have brand on the PDL? Yes.	5	0	0	Passes
	Glucocorticoids	Oral, Summary	New formulation Tarpeyo. No changes recommended.	5	0	0	Passes
	Immunomodulators	Asthma	No new information. No changes recommended.	5	0	0	Passes
Respiratory	Intranasal Rhinitis Agents		Nasonex discontinued as prescription strength; will be OTC strength. No changes recommended.	5	0	0	Passes
	Leukotriene Modifiers		No new information. No changes recommended.	5	0	0	Passes

2022 Schedule

September 20th

December 13th

Adjournment

The meeting adjourned at 9:48 AM.